Brokerages Set COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Price Target at $15.88

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $15.8750.

Several analysts have recently issued reports on CMPS shares. BTIG Research increased their target price on COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday, October 8th. Morgan Stanley raised their target price on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. HC Wainwright cut their price target on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, August 4th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price target on shares of COMPASS Pathways in a research report on Friday, August 1st.

COMPASS Pathways Stock Performance

Shares of NASDAQ:CMPS opened at $5.86 on Monday. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. COMPASS Pathways has a 12-month low of $2.25 and a 12-month high of $7.09. The company’s 50 day moving average price is $5.87 and its two-hundred day moving average price is $4.72. The firm has a market cap of $562.21 million, a PE ratio of -2.15 and a beta of 2.22.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. Equities research analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current year.

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently modified their holdings of the business. Alps Advisors Inc. lifted its position in shares of COMPASS Pathways by 19.7% during the 1st quarter. Alps Advisors Inc. now owns 66,231 shares of the company’s stock worth $189,000 after buying an additional 10,899 shares during the last quarter. Cerity Partners LLC acquired a new position in COMPASS Pathways during the first quarter worth about $29,000. ARK Investment Management LLC lifted its holdings in shares of COMPASS Pathways by 4.0% in the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company’s stock worth $5,162,000 after acquiring an additional 68,601 shares during the last quarter. BIT Capital GmbH boosted its stake in shares of COMPASS Pathways by 112.9% in the 1st quarter. BIT Capital GmbH now owns 246,320 shares of the company’s stock valued at $704,000 after purchasing an additional 130,623 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in shares of COMPASS Pathways during the 1st quarter valued at approximately $41,000. Institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.